Optomed Q4: Initial take – Sales in line and slightly higher costs than expected - Redeye
Bildkälla: Stockfoto

Optomed Q4: Initial take – Sales in line and slightly higher costs than expected - Redeye

Redeye provides an initial take following the release of Optomed’s Q4 2024 report. Sales aligned with our expectations, and costs were a bit higher than projected. Overall, we note that the company has a positive outlook for 2025, which will be an important year for the company. We will provide an update, digging deeper into the report.

Redeye provides an initial take following the release of Optomed’s Q4 2024 report. Sales aligned with our expectations, and costs were a bit higher than projected. Overall, we note that the company has a positive outlook for 2025, which will be an important year for the company. We will provide an update, digging deeper into the report.
Börsvärldens nyhetsbrev
ANNONSER